Per Gjorstrup, MD, PhD, is founder and chief scientific officer of Anida Pharma Inc. He also holds an adjunct professorship at SUNY College of Optometry in ocular immunology. Dr. Gjorstrup has a major research interest in translational medicine with a focus on immune-related disorders, including neuroinflammation, and has overseen seven first-in-man drug development programs, including novel oral treatments for multiple sclerosis. Dr. Gjorstrup’s current research focus, and has been for several years, is on the class of endogenous mediators called resolvins/protectins and their dual actions of regulating inflammation and cell survival, and he has recently directed the pre-clinical and clinical development of two such drug candidates into human studies. Dr. Gjorstrup received both his MD and PhD from the University of Lund, Sweden.